Publications by authors named "A M DeMarzo"
Objective: Increased glutamine metabolism by cancer cells via upregulation of the drug-targetable enzyme glutaminase may contribute to an immune-suppressive tumor microenvironment. Inhibiting glutamine metabolism can not only suppress tumor growth, but also enhance tumor-specific immunity. We investigated the relationship between glutaminase expression, the immune tumor microenvironment, and clinicopathologic features in endometrial cancer.
View Article and Find Full Text PDFBackground: Prostate cancer remains the most prevalent malignancy and the second-leading cause of cancer-related death in men in the USA. Radiation therapy, typically with androgen suppression, remains a mainstay in the treatment of intermediate- and high-risk, potentially lethal prostate cancers. However, local recurrence and treatment failure remain common.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed DNA from invasive pancreatic adenocarcinomas and precursor lesions of patients with and without ATM genetic variants to assess how these alterations contribute to cancer development.
- * Findings revealed that somatic ATM alterations were present in a significant majority of invasive cancers (75%) but were much less common in precursor lesions (7.1%), suggesting that alterations may occur later in the progression of pancreatic cancer.*
Due to their immunosuppressive role, tumor-infiltrating regulatory T cells (TI-Tregs) represent attractive immuno-oncology targets. Analysis of TI vs. peripheral Tregs (P-Tregs) from 36 patients, across four malignancies, identified 17 candidate master regulators (MRs) as mechanistic determinants of TI-Treg transcriptional state.
View Article and Find Full Text PDFPurpose Of Review: This is a pragmatic decision aid for initiating pharmacotherapy for stage 1 hypertension.
Recent Findings: If a stage 1 patient presents with clinical signs of fluid retention, then a diuretic should be the primary agent. However, if the patient is normovolemic, then a vasodilator should be the primary agent.